[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 293
Citations 0
Comment & Response
February 16, 2016

Pharmacy Expenditures for Children With Serious Chronic Illness—Reply

Author Affiliations
  • 1Department of Pediatrics, Stanford University School of Medicine, Palo Alto, California
  • 2Center for Health Policy and Center for Primary Care and Outcomes Research, Stanford University, Stanford, California
JAMA. 2016;315(7):706-707. doi:10.1001/jama.2015.16981

In Reply We agree with Drs Ruble and Brixner that not all patients with hemophilia are the same. These patients represent a wide range of severity, and the cost skewing within the group reflects that. Hemophilia is not unique in this—most serious pediatric conditions demonstrate a range in severity.

Ruble and Brixner accurately describe the reasons for this variation, including presence of inhibitors, and note that patients with inhibitors have higher costs of therapy.1 We do not dispute these facts. Our Research Letter was not meant to be a profile of patients with hemophilia in California, but an analysis of overall outpatient pharmacy expenditures by children with serious chronic illness.

First Page Preview View Large
First page PDF preview
First page PDF preview